Article Details

Ascendis Pharma Announces Recommended Phase 2 Dose and - GlobeNewswire

Retrieved on: 2022-10-03 12:01:06

Tags for this article:

Click the tags to see associated articles and topics

Ascendis Pharma Announces Recommended Phase 2 Dose and - GlobeNewswire. View article details on hiswai:

Excerpt

TransCon TLR7/8 Agonist is a novel investigational product candidate designed for sustained, localized release of resiquimod (a potent immune-response ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up